Your session is about to expire
← Back to Search
Continuous Glucose Monitor
Dexcom G6 Continuous Glucose Monitor for Type 1 Diabetes (IMPaCT Trial)
N/A
Waitlist Available
Led By Risa Wolf, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of Type 1 diabetes for >3 months
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-6 months
Awards & highlights
Summary
This trial aims to see if using the Dexcom G6 CGM system helps children with poorly controlled Type 1 diabetes manage their blood sugar better. The device continuously monitors blood sugar levels and provides real-time data. This could help these children and their caregivers make better decisions about their diabetes care.
Eligible Conditions
- Type 1 Diabetes
- Low Blood Sugar
- High Blood Sugar
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3-6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Personal CGM Use
Secondary outcome measures
Change in Hemoglobin A1c
Change in the Percent Time in Range Glucose Control
Using Personal CGM
Trial Design
1Treatment groups
Experimental Treatment
Group I: Dexcom G6 Continuous Glucose MonitorExperimental Treatment1 Intervention
Children with type 1 diabetes will wear a continuous glucose monitor (CGM) for 10 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexcom G6 Continuous Glucose Monitor
2021
N/A
~30
Find a Location
Who is running the clinical trial?
DexCom, Inc.Industry Sponsor
138 Previous Clinical Trials
29,791 Total Patients Enrolled
Johns Hopkins UniversityLead Sponsor
2,285 Previous Clinical Trials
14,843,039 Total Patients Enrolled
Risa Wolf, MDPrincipal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
164 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger